NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDOlaparib Lynparza® Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Olaparib Olaparib [Specialist Drug] Malignant Disease, Targeted Therapy Responsive Malignancy, Antineoplastic Drugs Antineoplastics, Other
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
NICE TA831: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NOT recommended, replaced by TA887)
NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer